Bendamustine in the Treatment of Chinese Patients With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab Treatment
This study has been completed.
Teva Branded Pharmaceutical Products, R&D Inc.
First Posted: May 11, 2012
Last Update Posted: August 28, 2017
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( Teva Branded Pharmaceutical Products, R&D Inc. )
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||April 28, 2017|
|Primary Completion Date:||April 28, 2017 (Final data collection date for primary outcome measure)|